

Serial No.: 10/532956  
Group Art Unit No.: 1624

**Amendments to the Claims:**

1. (Currently Amended): ~~{A compound}~~ selected from the group consisting of:  
N-[4-chloro-2-hydroxy-3-(4-methyl-piperazine -1-sulfonyl)-phenyl]-N'-(2-chloro-3-fluorophenyl)  
urea;  
N-[4-chloro-2-hydroxy-3-(4-(2-hydroxyethyl)-piperazine-1-sulfonyl)phenyl]-N'-(2-chloro-3-  
fluorophenyl) urea; and  
N-[4-chloro-2-hydroxy-3-(1-piperazinylsulfonyl)phenyl]-N'-(2-chloro-3-fluorophenyl) urea  
or a pharmaceutically acceptable salt thereof.
2. (Original): A pharmaceutical composition comprising a compound according to Claim 1  
and a pharmaceutically acceptable carrier or diluent.
3. (Currently Amended): A method of treating a chemokine mediated disease, wherein the  
chemokine binds to an IL-8 a or b receptor in a mammal, which method comprises  
administering to said mammal an effective amount of a compound according to Claim 1,  
wherein the disease is selected from the group consisting of asthma, chronic obstructive  
pulmonary disease and adult respiratory distress syndrome.
4. (Canceled)
5. (New): A method according to claim 3 wherein the disease is chronic obstructive  
pulmonary disease.